WO2000039135A2 - Insulin mimetics from honey - Google Patents
Insulin mimetics from honey Download PDFInfo
- Publication number
- WO2000039135A2 WO2000039135A2 PCT/GB1999/004378 GB9904378W WO0039135A2 WO 2000039135 A2 WO2000039135 A2 WO 2000039135A2 GB 9904378 W GB9904378 W GB 9904378W WO 0039135 A2 WO0039135 A2 WO 0039135A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- type
- column
- type substance
- honey
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to insulin mimetics as obtainable from honey, and in particular to cyclitol containing carbohydrates as obtainable from honey which have the biological activities of P or A-type inositolphosphoglycans (IPG).
- IPG inositolphosphoglycans
- IPG inositol phosphoglycan
- GPI glycosyl phosphatidylinositol
- IPGs mediate the action of a large number of growth factors including insulin, nerve growth factor, hepatocyte growth factor, insulin-like growth factor I (IGF-I) , fibroblast growth factor, transforming growth factor ⁇ , the action of IL-2 on B-cells and T-cells, ACTH signalling of adrenocortical cells, IgE, FSH and hCG stimulation of granulosa cells, thyrotropin stimulation of thyroid cells, cell proliferation in the early developing ear and rat mammary gland.
- IGF-I insulin-like growth factor I
- fibroblast growth factor transforming growth factor ⁇
- ACTH signalling of adrenocortical cells IgE, FSH and hCG stimulation of granulosa cells
- thyrotropin stimulation of thyroid cells cell proliferation in the early developing ear and rat mammary gland.
- Soluble IPG fractions have been obtained from a variety of animal tissues including rat tissues (liver, kidney, muscle, brain, adipose, heart) and bovine liver. IPG biological activity has also been detected in malaria parasitized RBC and mycobacteria .
- the family of IPG second messengers have been divided into distinct A and P-type subfamilies on the basis of their biological activities. In the rat, release of the A- and P-type mediators has been shown to be tissue-specific (Kunjara et al, 1995) .
- W098/11116 and 098/11117 disclose the purification, isolation and characterisation of P and A-type IPGs from human tissue. Prior to these applications, it had not been possible to isolate single components from the tissue derived IPG fractions, much less in sufficient quantities to allow structural characterisation.
- honey can be a source of insulin mimetics, in particular inositolphosphoglycans such as P and A-type IPGs.
- inositolphosphoglycans such as P and A-type IPGs.
- the results described herein show that purified fractions obtained from honey have characteristic biological properties of IPGs, such as activating pyruvate dehydrogenase (PDH) phosphatase (P-type) , inhibition of cAMP dependent protein kinase (P and A-types) and induction of lipogenesis in adipocytes (A-type) .
- PDH pyruvate dehydrogenase
- P-type inhibition of cAMP dependent protein kinase
- A-type induction of lipogenesis in adipocytes
- the present invention provides the first demonstration that IPGs are the source of the insulin mimetic activity of honey and that it is possible to use honey as a natural source material from which IPGs can be isolated and purified.
- Honey is a mixture of carbohydrates, mainly monosaccharides, mixed with disaccharides and trisaccharides .
- monosaccharides is inositol which accounts for 0.01 to 0.20% of the total sugars (Horvath et al, 1997). Therefore, the presence of inositol in honey supports the hypothesis that the insulin mimetic agents extracted could be inositolphosphoglycans, especially as they elute from anion exchange resins at pH 2.0 and 1.3, activate pyruvate dehydrogenase phosphatase, and inhibit cAMP dependent protein kinase, in addition to lowering blood glucose.
- the insulin mimetic agent in low doses stimulated lipogenesis from glucose, but was inhibitory at higher doses.
- the insulin mimetic activity was purified from honey and can be readily isolated by methods used for the extraction of IPGs from animal tissues.
- the biological activity of the extracts may be considered as pro-drugs for the management of the hyperglycaemia and probably the lipodystrophy of diabetes .
- the present invention provides a substance as obtainable from honey, wherein the substance is a cyclitol containing carbohydrate which is :
- the present invention provides a P or A-type substance purified from honey.
- purified means that composition or fraction including the IPGs is free from one or more of the contaminants with which it is associated in bee honey, e.g. non-cyclitol containing carbohydrates, proteins or nucleotides.
- the IPGs are purified 2000 to 7000 fold from bee honey and could be further purified to isolation using the methods described in W098/11116, W08/11117 or as set out in Caro et al, 1997. Alternatively or additionally, purification or isolation can be carried out using cellulose in column chromatography as described below.
- the present invention provides a P or A-type substance as obtainable from honey by:
- the present invention provides the use of honey as a source material for the purification or isolation of P or A-type substances.
- the present invention provides the use of cellulose column chromatography in the purification of P or A-type substances.
- the present invention provides a method of purifying or isolating IPGs, such as the P or A-type substances disclosed herein, the method comprising contacting a sample containing IPGs with a column containing cellulose, and eluting the IPGs from the column.
- the method employs microcrystalline cellulose.
- the IPG-containing fraction is dissolved 4/1/1 butanol/water/ethanol (B:W:E) and loaded onto the column.
- the column is preferably washed with B:W:E and methanol, and then eluted with water and HC1 and the eluates collected. The eluates can then be concentrated and freeze dried.
- the cellulose purification corresponds to the conditions used in the examples.
- the present invention provides a pharmaceutical composition comprising P and/or A-type substance, or purified fraction comprising a P and/or A- type substance, as obtainable from honey, in combination with a carrier.
- the present invention provides the use of a P or A-type substance as obtainable from honey for the preparation of a medicament for the treatment of a condition characterised by a deficiency or imbalance of the IPGs.
- a condition characterised by a deficiency or imbalance of the IPGs e.g. as growth factor second messengers.
- A-type mediators modulate the activity of a number of insulin-dependent enzymes such as cAMP dependent protein kinase (inhibits) , adenylate cyclase (inhibits) and cAMP phospho-diesterases (stimulates) .
- P-type mediators modulate the activity of insulin-dependent enzymes such as pyruvate dehydrogenase phosphatase (stimulates), glycogen synthase phosphatase (stimulates) and cAMP dependent protein kinase (inhibits) .
- the A-type mediators mimic the lipogenic activity of insulin on adipocytes, whereas the P-type mediators mimic the glycogenic activity of insulin on muscle. Both A-and P-type mediators inhibit cAMP dependent protein kinase and are mitogenic when added to fibroblasts in serum free media. The ability of the mediators to stimulate fibroblast proliferation is enhanced if the cells are transfected with the EGF- receptor. A-type mediators can stimulate cell proliferation in the chick cochleovestibular ganglia.
- Soluble IPG fractions having A-type and P-type activity have been obtained from a variety of animal tissues including rat tissues (liver, kidney, muscle brain, adipose, heart) and bovine liver.
- A- and P-type IPG biological activity has also been detected in human liver and placenta, malaria parasitized RBC and mycobacteria .
- the ability of an anti-inositolglycan antibody to inhibit insulin action on human placental cytotrophoblasts and BC3H1 myocytes or bovine-derived IPG action on rat diaphragm and chick cochleovestibular ganglia suggests cross-species conservation of many structural features.
- A-type substances are cyclitol-containing carbohydrates, also containing Zn 2+ ion and optionally phosphate and having the properties of regulating lipogenic activity and inhibiting cAMP dependent protein kinase. They may also inhibit adenylate cyclase, be mitogenic when added to EGF-transfected fibroblasts in serum free medium, and stimulate lipogenesis in adipocytes.
- P-type substances are cyclitol-containing carbohydrates, also containing Mn 2+ and/or Zn 2+ ions and optionally phosphate and having the properties of regulating glycogen metabolism and activating pyruvate dehydrogenase phosphatase. They may also stimulate the activity of glycogen synthase phosphatase, be mitogenic when added to fibroblasts in serum free medium, and stimulate pyruvate dehydrogenase phosphatase.
- the mediators and analogues of the invention can be formulated in pharmaceutical compositions.
- These compositions may comprise, in addition to one or more of the mediators, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- a pharmaceutically acceptable excipient e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes .
- compositions for oral administration may be in tablet, capsule, powder or liquid form.
- a tablet may include a solid carrier such as gelatin or an adjuvant.
- Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
- the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
- isotonic vehicles such as sodium chloride injection, Ringer's injection, lactated Ringer's injection.
- Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
- the pharmaceutically useful compound according to the present invention is given to an individual in a "prophylactically effective- amount” or a “therapeutically effective amount” (as the case may be, although prophylaxis may be considered therapy) , this being sufficient to show benefit to the individual.
- this will be to cause a therapeutically useful effect, e.g. in the treatment of diabetes.
- the actual amount of the compounds administered, and rate and time- course of administration, will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.
- compositions disclosed herein can be used in the treatment of conditions involving a deficiency of a P or A-type substance and conditions in which the ratio of P and A-type substances is imbalanced, e.g. by administering one of the substance or an antagonist to correct the ratio of the substances.
- compositions of the invention can be used in the treatment of diabetes, including diabetes due to insulin resistance, insulin resistance in type I diabetes and brittle diabetes.
- the compositions may also be used to treat other conditions mediated by insulin, and in particular insulin resistance or insulin underproduction such as lipotrophic disorders or polycystic ovary disease.
- the application describes the treatment of obese type II diabetes (NIDDM) patients with a P-type IPG and/or an A-type IPG antagonist and the treatment of IDDM (type I diabetes) or lean type II diabetes (NIDDM) (body mass index ⁇ 27) with a mixture of P and A-type IPGs, typically in a P:A ratio of about 6:1 for males and 4:1 for females.
- IDDM type I diabetes
- NIDDM lean type II diabetes
- the IPGs isolated or purified from honey as described herein can be employed in the treatment of diabetes described in the earlier application.
- the IPGs from honey disclosed herein could be used in the treatment of other conditions characterised by a deficiency or imbalance of P and/or A- type IPGs.
- Acid washed charcoal was washed in deionized water to remove fines and filtered using a Buchner funnel and flask. The fined charcoal was then dried in ai * r at room temperature.
- the supernatant was mixed with 25 ml of settled BioRad AG1X8 (formate) pH 4.5 and gently mixed on an orbital shaker for 20 hours at 4°C.
- the resin was transferred to a column and washed with 5 bed-volumes (125ml) water, and then with 5 bed-volumes (125 ml) of 1 mmol/1 HCl pH 3.0.
- One fraction containing the insulin mimetic activity was then eluted with 10 bed-volumes (250 ml) of 10 mmol/1 HCl (pH 2.0).
- a second fraction containing an insulin mimetic activity was eluted with 10 bed-volumes (250 ml) of 50 mmol/1 HCl (pH 1.3).
- the pH of the eluates was then adjusted to 4.0 with 10% NH 4 OH, and then were concentrated under reduced pressure in a rotary evaporator at 37°C.
- the concentrated eluates were then lyophilised.
- the pH 2.0 fraction was further purified using the pH 2.0 fraction clean-up procedure described belo .
- the prepared cellulose was suspended in 50% ethanol/water and about 2 ml was transferred to each column and allowed to settle.
- the settled cellulose was washed with 5 ml deionized H 2 0 and the liquid level was allowed to drain to the top of the cellulose.
- the column was then washed with 5 ml butanol : water : ethanol (B:W:E) (4:1:1) and the liquid level allowed to drain to the top of the column.
- the columns were then capped and stored at 4°C prior to use.
- the freeze-dried pH 2.0 fraction prepared above was dissolved in 500 ⁇ l B:W:E (4:1:1), and the solution loaded onto the column and allowed to drain into the top of the cellulose.
- the column was washed with 5 ml B:W:E (4:1:1) and 5 ml methanol, and the washings discarded.
- the column was then eluted with (a) 5 ml deionized water and the eluate collected (W) and (b) 10 ml of 50 mM HCl (pH 1.3) and the eluate collected (A).
- the eluates were then concentrated in a Vapour-Mix concentrator and then freeze dried.
- Mixture A 1 part coenzyme A (60 mg +60 ml 3.2 mM DTT) , 1 part dithiothreitol (DTT) (3.2 mM) , 1 part NAD (25 mM) , 1 part dipotassium hydrogen phosphate (KPi) (500 mM/pH 8.0), 1 part thiamine pyrophosphate . HCl (TPP) (2 mM) and 5 parts water.
- Mixture A was stored in 10 ml aliquots.
- Mixture B 1 part ATP (10 mM) , 1 part DTT (10 mM) , 1 part ethylene glycol tetraacetic acid (EGTA) (1 M) , 1 part MgCl 2 (10 mM) , 1 part KPi (200 mM/pH 7.0), 3 parts water. Mixture B was stored in 0.4 ml aliquots.
- Mixture C 4 parts BSA (1 mg/ml), 1 part CaCl 2 (l mM) , 1 part DTT (10 mM) , 1 part MgCl 2 (100 mM) , 1 part KPi 200 mM/pH 7.0. Mixture C was stored in 2 ml aliquots.
- NaF 780 mM NaF was stored in 1.5 ml aliquots.
- Pyruvate 40 mM pyruvate (PYR) was stored in 0.5 ml aliquots .
- PDH (100 ⁇ l) was added to a tube containing reaction mixture B and was mixed and incubated at 30°C for 15 minutes (or until PDH activity was 99% inactivated) . The mixture was stored in ice. A 50 ⁇ l aliquot of this mixture was transferred to each cuvette for the assay. Mixture C (200 ⁇ l) was then added and mixed well, and the resulting mixture incubated at 30°C for 3 minutes. The test solution (10-20 ⁇ l) was then added, followed by PDH phosphatase (10 ⁇ l), and the resulting solution mixed well and incubated at 30°C for 3 minutes. Next, 50 ⁇ l NaF was added followed by mixture A (1000 ⁇ l) with mixing. The PDH assay was started by the addit ' ion of 50 ⁇ l pyruvate, and the absorbance at 340 nm was recorded for at least 5 minutes.
- Reaction buffer ATP (10 mM) , MgCl 2 (50 mM) , 0.01% Triton X-100, Tris (100 mM/pH 7.4).
- Activator solution 500 ⁇ M cAMP in water.
- PKA substrate 1.2 mg Kemptide (LRRASLG) labelled with a fluorescent probe in 550 ⁇ l 1% BSA.
- Phosphopeptide binding buffer NaAc (0.1 M) , NaCl (0.5 M, 0.2% NaN 3 , pH 5.0.
- Phosphopeptide elution buffer NH 4 HC0 3 (0.1 M) , 0.02% NaN 3 , pH 8.0.
- Reaction buffer, PKA substrate and activator solution (5 ⁇ l each) were premixed for each test sample. Duplicates of the following solutions were pipetted into the tubes:
- binding buffer 250 ⁇ l was then applied to each unit and incubated for 3 minutes at room temperature. The units were then centrifuged at 6500 rpm for 1 minute. A further aliquot of binding buffer (250 ⁇ l) was applied to the unit, followed by incubation for 3 minutes, and centrifugation at 6500 rpm for 1 minute. The binding buffer collected contained the non-phosphorylated Kemptide. Elution buffer (250 ⁇ l) was applied to each unit and was incubated for 3 minutes at room temperature, and then centrifuged at 6500 rpm for 1 minute. This step was repeated. The collected binding buffer contains the phosphorylated Kemptide.
- the eluate (250-300 ⁇ l) was transferred to individual wells of a flat-bottom 96-well plate and the absorbance at 570 nm read using a spectrophotometer or a fluorometer (with excitation at 573 nm and emission at 589 nm) .
- Epididymal fat pads from three rats were dissected out and chopped finely with scissors in a plastic weighing boat containing some Krebs Ringer Hepes Albumin buffer (KRHA) .
- KRHA Krebs Ringer Hepes Albumin buffer
- the KRHA was decanted and the adipose tissue suspended in fresh KRHA (15 ml) containing 30 mg collagenase-D and 2% BSA (fatty acid free) .
- the suspension was incubated in a water bath at 37°C with shaking, until the end point of the digestion .(45-50 minutes).
- the fat fragments were aspirated several times to obtain a homogenous suspension, the suspension strained, diluted with KRHA to 30 ml and centrifuged at room temperature.
- the supernatant was withdrawn and replaced with fresh KRHA (30 ml) and the adipocytes resuspended by gentle mixing. The centrifugation steps were repeated twice more. The adipocytes were then suspended in 30 ml KRHA in a shaking water bath with gassing (0 2 /C0 2 95:5)
- a vial was loaded with 500 ⁇ l substrate (KRHA and U 14 C-glucose) and the test solution or 1 nM insulin as positive control.
- Samples of the adipocyte suspension (0.5 ml), and an eppendorf tube were inserted, the vial sealed and gassed for 10 minutes. Gassing was then stopped and the suspension incubated for 2 hours.
- hyamine hydroxide (0.2 ml) was injected into the eppendorf tube followed by HCl (0.2 ml/6N) into the incubation mixture. The vial was allowed to equilibrate for 60 minutes, after which the hyamine hydroxide was transferred to a clean vial using methanol. Scintillation cocktail (4 ml) was added and 14 C0 2 was counted.
- the vial contents were transferred to a tube using isopropanol/hexane/H 2 S0 4 (40/10/1) .
- Hexane and water were added with vigorous mixing and the phases allowed to separate.
- An aliquot of H 2 S0 4 (0.001 N) was added.
- the phases were then separated by centrifugation at 500 x g for 10 minutes at 4°C.
- the hexane phase was then transferred to a pico vial, allowed to dry in a fume hood.
- the resulting lipid was dissolved in 4 ml non- aqueous scintillation mixture, and the radioactivity incorporated into lipids was counted.
- 0.05 M citrate buffer pH 4.5 was prepared by dissolving 1.05 g citric acid monohydrate in 80 ml 0.154 M NaCl and adjust pH to 4.5 with 1.0 M NaOH. The volume was made up to 100 ml with 0.154 M NaCl.
- Streptozotocin (STZ) was prepared by dissolving 100 mg streptozotocin in 1.6 ml 0.05 M citrate buffer pH 4.5 in 0.154 M NaCl.
- Each rat was injected with 0.2 ml of STZ i.v. through the tail vein. Rats were tested for hyperglycaemia and used one week later. pH 1.3 or 2.0 fractions were injected i.v. in the doses indicated below in 0.20 ml PBS (Fonteles et al, 1996) .
- honey contains both A and P-type activities in comparable amounts.
- the A-type stimulated glucose oxidation and lipogenesis in adipocytes in a dose-dependent manner. However, as high doses, there was an inhibition of lipogenesis implying that there may be more than one component in the fraction . Effect of IPGs from honey on blood glucose of streptozotocin diabetic rats
- W098/11116, W098/11117 and W098/11435 (Hoeft Rademacher Limited) .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Insects & Arthropods (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Jellies, Jams, And Syrups (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0110533A GB2358860A (en) | 1998-12-23 | 1999-12-23 | Insulin mimetics from honey |
AU18781/00A AU1878100A (en) | 1998-12-23 | 1999-12-23 | Insulin mimetics from honey |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9828559.6 | 1998-12-23 | ||
GBGB9828559.6A GB9828559D0 (en) | 1998-12-23 | 1998-12-23 | Insulin mimetics from honey |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000039135A2 true WO2000039135A2 (en) | 2000-07-06 |
WO2000039135A3 WO2000039135A3 (en) | 2000-12-14 |
Family
ID=10844983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/004378 WO2000039135A2 (en) | 1998-12-23 | 1999-12-23 | Insulin mimetics from honey |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU1878100A (en) |
GB (2) | GB9828559D0 (en) |
WO (1) | WO2000039135A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003031472A2 (en) * | 2001-10-09 | 2003-04-17 | N.V. Nutricia | Insulin mimetic amino acid sequences |
WO2005034969A1 (en) * | 2003-10-17 | 2005-04-21 | Camelyn, Ltd. | Medicament on the basis of honey, preparation and use thereof |
GB2438965B (en) * | 2006-06-06 | 2011-09-07 | Rasha Alhaj | A method of producing heat stable, water-soluble compounds of greater than 100kDa from honey for treatment of breast cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998011117A1 (en) * | 1996-09-11 | 1998-03-19 | Rademacher Group Limited | Cyclitol containing carbohydrates from human tissue which regulate glycogen metabolism |
WO1998011116A1 (en) * | 1996-09-11 | 1998-03-19 | Rademacher Group Limited | Cyclitol containing carbohydrates from human tissue which regulate lipogenic activity |
-
1998
- 1998-12-23 GB GBGB9828559.6A patent/GB9828559D0/en not_active Ceased
-
1999
- 1999-12-23 WO PCT/GB1999/004378 patent/WO2000039135A2/en active Application Filing
- 1999-12-23 AU AU18781/00A patent/AU1878100A/en not_active Abandoned
- 1999-12-23 GB GB0110533A patent/GB2358860A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998011117A1 (en) * | 1996-09-11 | 1998-03-19 | Rademacher Group Limited | Cyclitol containing carbohydrates from human tissue which regulate glycogen metabolism |
WO1998011116A1 (en) * | 1996-09-11 | 1998-03-19 | Rademacher Group Limited | Cyclitol containing carbohydrates from human tissue which regulate lipogenic activity |
Non-Patent Citations (2)
Title |
---|
K. HORVATH ET AL.: "Simultaneous quantitation of mono-, di-, and trisaccharides by GC-MS of their TMS ether oxime derivatives: II. In honey" CHROMATOGRAPHIA, vol. 45, 1997, pages 328-335, XP000920509 cited in the application * |
S.W. HOMANS ET AL.: "Complete structure of the glycosyl phosphatidylinositol membrane anchor of rat brain Thy-1 glycoprotein" NATURE, vol. 333, 1988, pages 269-272, XP002140288 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003031472A2 (en) * | 2001-10-09 | 2003-04-17 | N.V. Nutricia | Insulin mimetic amino acid sequences |
WO2003031472A3 (en) * | 2001-10-09 | 2004-03-25 | Nutricia Nv | Insulin mimetic amino acid sequences |
WO2005034969A1 (en) * | 2003-10-17 | 2005-04-21 | Camelyn, Ltd. | Medicament on the basis of honey, preparation and use thereof |
EA012294B1 (en) * | 2003-10-17 | 2009-08-28 | Камелин Лтд. | Medicaments made on the basis of honey, their use and a method for preparation thereof |
GB2438965B (en) * | 2006-06-06 | 2011-09-07 | Rasha Alhaj | A method of producing heat stable, water-soluble compounds of greater than 100kDa from honey for treatment of breast cancer |
Also Published As
Publication number | Publication date |
---|---|
GB9828559D0 (en) | 1999-02-17 |
AU1878100A (en) | 2000-07-31 |
GB0110533D0 (en) | 2001-06-20 |
GB2358860A (en) | 2001-08-08 |
WO2000039135A3 (en) | 2000-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meissner | Adenine nucleotide stimulation of Ca2+-induced Ca2+ release in sarcoplasmic reticulum. | |
Ikegami et al. | Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-α | |
Dawson et al. | The phospholipids of the erythrocyteghosts' of various species | |
Schneider et al. | Increased cystine in leukocytes from individuals homozygous and heterozygous for cystinosis | |
Grodsky et al. | Effect of pulse administration of glucose or glucagon on insulin secretion in vitro | |
Tulsiani et al. | The similar effects of swainsonine and locoweed on tissue glycosidases and oligosaccharides of the pig indicate that the alkaloid is the principal toxin responsible for the induction of locoism | |
Drury | Method for the preparation of active maturation promoting factor (MPF) from in vitro matured oocytes of Xenopus laevis | |
Natalizi et al. | Purification of insect hyperglycaemic and heart accelerating hormones | |
US6303580B1 (en) | Cyclitol Containing carbohydrates from human tissue which regulate lipogenic activity | |
Gerber III et al. | GABA in peripheral tissues: presence and actions in endocrine pancreatic function | |
WO2000039135A2 (en) | Insulin mimetics from honey | |
EP0932410B1 (en) | Mistletoe (viscum) extracts | |
CN110016007B (en) | Cyclic diphenylheptanes, preparation method thereof, application thereof, medicament and dietary supplement | |
Chiba et al. | Potential mediation of somatostatin secretion from canine fundic D-cells by protein kinase C | |
WO2000038698A2 (en) | Substances from porcine tissue | |
Banczerowski et al. | Lesion of the amygdala on the right and left side suppresses testosterone secretion but only left-sided intervention decreases serum luteinizing hormone level | |
Chiba et al. | Mechanism for increase of gastrin release by secretin in Zollinger-Ellison syndrome | |
Porter et al. | Reaction of brain copper proteins with sodium diethyldithiocarbamate in normal and in hepatolenticular degeneration. | |
Elased et al. | Improvement of glucose homeostasis in obese diabetic db/db mice given Plasmodium yoelii glycosylphosphatidylinositols | |
Bradford et al. | Effects of local anesthetics on phospholipid topology and dopamine uptake and release in rat brain synaptosomes | |
Bigon et al. | Lysophosphatidylserine‐induced release of intracellular amines in mice | |
Egawa et al. | Effect of parathyroid extract on the metabolism of radioactive phosphate in kidney | |
EP1337538A1 (en) | Phosphoglycan messengers and their medical uses | |
US20130189298A1 (en) | Novel yeast strain and the application thereof | |
Qureshi et al. | ANTI HYPERGLYCEMIC AND ANTI DYSLIPIDEMIC EFFECTS OF FLAX SEEDS (LINUM USITATISSIMUM) EXTRACT IN DIABETIC RATS MODEL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase in: |
Ref country code: GB Ref document number: 200110533 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09868736 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |